Organisation paid for research Program year 2025 Source: CMS Open Payments

Studymetrix Research

Neither a doctor nor a teaching hospital

Research payments

$796,892

514 payments

Through program year 2025, Studymetrix Research is reported as receiving $796,892 in research payments, across 514 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$108,056	5
2024	Research	$178,370	13
2023	Research	$106,731	38
2022	Research	$107,548	367
2021	Research	$103,438	22
2020	Research	$191,332	66
2019	Research	$1,417	3

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $310,979 22 payments
Novo Nordisk AS $275,876 461 payments
Novartis Pharmaceuticals Corporation $140,343 8 payments
Pfizer Inc. $22,501 14 payments
AbbVie, Inc. $19,177 4 payments
Biogen, Inc. $11,550 1 payment
Boehringer Ingelheim Pharmaceuticals, Inc. $10,105 2 payments
Boehringer Ingelheim International GmbH $6,361 2 payments

Studies the money was for Research payments · program years 2019–2025

Ph2 Obesity $135,657 2 payments
Nn9536-4378 $96,380 60 payments
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $95,317 3 payments
Nn9535-4984 $88,855 248 payments
Nn9536-4373 $60,835 10 payments
A Multicenter, Open Label Study Assessing the Efficacy of erenumab on Interictal Migraine Related Burden $54,348 3 payments
A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $45,026 5 payments
Work Productivity Study $43,377 7 payments
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus $30,718 1 payment
Erenumab - Comprehensive Assessment of Efficacy (EMBRACE) $30,331 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.